

EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")

Notice of Interim Results & Investor Presentation

Notice of Results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that the Company will announce its interim results for the six months ended 30 June 2022 on Tuesday 20 September 2022.

Investor Presentation

Mike Salter, Chief Executive Officer, and Marc Davies, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30 pm on Tuesday 20 September 2022. The presentation is open to all existing and potential investors.

Investors can sign up to Investor Meet Company for free and register for the presentation

here: <https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor>

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

EKF Diagnostics Holdings plc
Mike Salter, CEO / Marc Davies, CFO

www.ekfdiagnostics.com
Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker)
Aubrey Powell / George Tzimas

Tel: +44 (0)20 7496 3000

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams / Ben Farrow

Tel: +44 (0)20 7597 4000

Walbrook PR Limited

Paul McManus / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or
ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

Point-of-Care	Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
Central Laboratory	Clinical chemistry, Small lab analysers, Centrifuges <i>Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin</i>
Life Sciences	Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing	Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
Laboratory Services	In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results.

EKF's growth strategy to 2024 and beyond can be summarised as:

- continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships;
- investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses;
- expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and
- concluding complementary earnings-enhancing acquisitions with key strategic value.

EKF will also continue to generate enhanced shareholder value through:

- a progressive dividend policy; and
- its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities such as those already seen with Renalytix plc, Verici Dx plc and Trelus Health plc.

Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOREAKPFDADAEFA Anonymous (not verified) Notice of Interim Results & Investor Presentation
32930076 A Thu, 09/01/2022 - 07:00 LSE RNS Advance Notice of Results EKF